| PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression S Jiao, W Xia, H Yamaguchi, Y Wei, MK Chen, JM Hsu, JL Hsu, WH Yu, ... Clinical Cancer Research 23 (14), 3711-3720, 2017 | 870 | 2017 |
| Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors Y Du, H Yamaguchi, Y Wei, JL Hsu, HL Wang, YH Hsu, WC Lin, WH Yu, ... Nature medicine 22 (2), 194-201, 2016 | 229 | 2016 |
| Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing L Sun, RY Yang, CW Li, MK Chen, B Shao, JM Hsu, LC Chan, Y Yang, ... American journal of cancer research 8 (7), 1307-1316, 2018 | 114 | 2018 |
| Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases MK Chen, MC Hung FEBS journal 282 (19), 3693-3721, 2015 | 96 | 2015 |
| Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death J Houl, Z Ye, C Brosey, L Balapiti-Modarage, S Namjoshi, A Bacolla, ... Nature Communications 10 (1), 5654, 2019 | 93 | 2019 |
| Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer YH Hsu, J Yao, LC Chan, TJ Wu, JL Hsu, YF Fang, Y Wei, Y Wu, ... Cancer research 74 (17), 4822-4835, 2014 | 75 | 2014 |
| EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma Q Dong, Y Du, H Li, C Liu, Y Wei, MK Chen, X Zhao, YY Chu, Y Qiu, L Qin, ... Cancer research 79 (4), 819-829, 2019 | 60 | 2019 |
| Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer YY Chu, C Yam, MK Chen, LC Chan, M Xiao, YK Wei, H Yamaguchi, ... Am J Cancer Res 10 (2), 648-661, 2020 | 38 | 2020 |
| Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells Y Han, MK Chen, HL Wang, JL Hsu, CW Li, YY Chu, CX Liu, L Nie, ... American journal of cancer research 9 (3), 608-618, 2019 | 32 | 2019 |
| H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bounded retrograde trafficking mechanism MK Chen, Y Du, L Sun, JL Hsu, YH Wang, Y Gao, J Huang, MC Hung Journal of Biological Chemistry 294 (21), 8516-8528, 2019 | 24 | 2019 |
| Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma X Sun, CW Li, WJ Wang, MK Chen, H Li, YJ Lai, JL Hsu, PB Koller, ... Am J Cancer Res 10 (2), 564-571, 2020 | 23 | 2020 |
| Nuclear receptor tyrosine kinase transport and functions in cancer MK Chen, JL Hsu, MC Hung Advances in Cancer Research 147, 59-107, 2020 | 19 | 2020 |
| Regulation of therapeutic resistance in cancers by receptor tyrosine kinases MK Chen, MC Hung American Journal of Cancer Research 6 (4), 827, 2016 | 19 | 2016 |
| Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells Y Gao, MK Chen, YY Chu, L Yang, D Yu, Y Liu, MC Hung American Journal of Cancer Research 11 (1), 236, 2021 | 13 | 2021 |
| Delay of gap filling during nucleotide excision repair by base excision repair: the concept of competition exemplified by the effect of propolis MK Chen, YC Tsai, PY Li, CC Liou, ES Taniga, DW Chang, T Mori, YC Liu Toxicological Sciences 122 (2), 339-348, 2011 | 13 | 2011 |
| PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation Z Xue, S Zheng, D Linghu, B Liu, Y Yang, MK Chen, H Huang, J Song, ... American Journal of Cancer Research 12 (5), 2363, 2022 | 11 | 2022 |
| Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma D Wang, H Luo, Z Huo, MK Chen, Z Han, M Hung, B Su, Y Li, X Wang, ... American journal of cancer research 9 (3), 479-495, 2019 | 11 | 2019 |
| Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex YY Chu, MK Chen, Y Wei, HH Lee, W Xia, YN Wang, C Yam, JL Hsu, ... Nature Cancer 3 (10), 1211-1227, 2022 | 10 | 2022 |
| Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer MK Chen The FEBS Journal, DOI: 10.1111/febs.15730, 2021 | 6 | 2021 |
| A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma CT Chen, YC Chen, Y Du, Z Han, H Ying, RR Bouchard, JL Hsu, JM Hsu, ... American Journal of Cancer Research 7 (3), 657, 2017 | 6 | 2017 |
Mien-Chie HungChina Medical University, Taiwan在 cmu.edu.tw 的电子邮件经过验证
